Study wrapper · #822
Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.
Editor's note
A network meta-analysis of 43 randomized trials (3,379 participants) examining what GLP-1 receptor agonists do to body composition — not just scale weight, but fat versus lean tissue measured directly. It is agent-level, so both tracked peptides surface: subcutaneous semaglutide 1.0 mg weekly and tirzepatide 15 mg weekly are named, alongside liraglutide, as agents associated with statistically significant loss of lean mass from baseline (standardized mean differences roughly -0.50 to -1.09). The headline is nuanced and worth surfacing carefully: these drugs substantially reduced total body fat, fat mass, visceral and subcutaneous fat, and liver fat, but the lean-mass finding — especially at higher doses — is the clinically important caveat the muscle-preservation conversation has been circling. As meta-analytic RCT evidence this ranks well, though network meta-analyses depend on trial comparability and body-composition measurement varied across studies. A substantive, peptide-specific data point on the fat-versus-muscle question.
Plain-language abstract
This study combined 43 randomized trials involving nearly 3,400 people to look closely at how GLP-1 weight-loss medications change body composition — that is, not just how much weight people lose, but whether they lose fat, muscle, or both. Researchers measured things like total body fat, fat around the organs (visceral fat), fat under the skin, and fat in the liver, as well as lean (muscle) tissue. The injectable GLP-1 drugs clearly reduced fat in all these areas compared with control groups, which is the intended effect. However, the study also found a downside: certain drugs and doses — including weekly semaglutide 1.0 mg and weekly tirzepatide 15 mg, along with a dose of liraglutide — were linked to a meaningful loss of muscle mass, especially at higher doses. In plain terms, these medications strip away fat effectively but may also cost some muscle, which is a growing concern among doctors. Because this pooled the results of many trials that measured body composition in different ways, the muscle finding is an important signal to weigh rather than a precise number.